Lifevantage Corp. (LFVN)
NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-09-04
NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-09-04
QuarterlyIQ Insights · LFVN
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $6.25 LFVN trades at 11× p/e, below its 13× p/e peer median, but our blended $6.20 fair value is roughly in line with the price. It's a high-confidence read. Even valued only for durable growth at sustainable margins, it's worth about $7.48 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $8.67 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $9.65 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $3.94 | — | — | TTM | high |
| graham number | 12M | $5.78 | — | — | TTM | high |
| Peer EV/EBITDA | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $7.95 |
| 8.5 |
| 0.82 |
| TTM |
| high |
| Peer P/FCF | 12M | $3.47 | 11.7 | 0.30 | TTM | high |
| Peer P/E | 12M | $7.02 | 12.5 | 0.56 | TTM | high |
| Peer P/S | 12M | $10.67 | 0.7 | 14.42 | TTM | high |
| residual income | 12M | $4.20 | — | — | TTM | high |
| Own P/E history | 12M | $5.81 | 10.4 | 0.56 | TTM | high |
| triangulated | 12M | $6.96 | 12.5 | 0.55 | Triangulated | high |
| Peer P/FCF | 3Y | $4.34 | 11.7 | 0.37 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $6.91 | 12.5 | 0.55 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $9.13 | 0.7 | 12.34 | Hist. CAGR(prov.) | medium |
| Own P/E history | 3Y | $5.71 | 10.4 | 0.55 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $5.03 | 11.7 | 0.43 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $6.22 | 12.5 | 0.50 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $8.23 | 0.7 | 11.12 | Hist. CAGR(prov.) | high |
| Own P/E history | 5Y | $5.15 | 10.4 | 0.50 | Hist. CAGR(prov.) | high |